Mark S. Shearman - 10 Feb 2022 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role: EVP, CHIEF SCIENTIFIC OFFICER
Signature: /s/ Mark Shearman
Issuer symbol: EDIT
Transactions as of: 10 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 11 Feb 2022, 15:21:17 UTC
Previous filing: 23 Dec 2021
Next filing: 16 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EDIT	Common Stock	Award	$0	+31,709	+76%	$0.000000	73,494	10 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EDIT	Stock Option (right to buy)	Award	$0	+93,398		$0.000000	93,398	10 Feb 2022	Common Stock	93,398	$17.29	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 10, 2023 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 10, 2026.
F2	This option was granted on February 10, 2022 and is scheduled to vest over four years in equal monthly installments beginning on March 10, 2022 through February 10, 2026.